Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Fineline Cube Apr 21, 2026
Company Drug

Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers

Fineline Cube Apr 21, 2026
Company Hospital

Innovent Biologics Launches Phase I Clinical Trial for IBR822 Cell Injection Solution in Solid Tumors

Fineline Cube Sep 16, 2024

Innovent Biologics (Hangzhou) Co., Ltd (HKG: 1801, OTCMKTS: IVBXF), a biopharmaceutical company based in China,...

Company Drug

Johnson & Johnson’s Tremfya Gains FDA Approval for Ulcerative Colitis Treatment

Fineline Cube Sep 14, 2024

Johnson & Johnson (NYSE: JNJ) announced today that the US Food and Drug Administration (FDA)...

Company Deals

Sanofi Secures Global Rights to Radioligand Therapy AlphaMexi in Deal with RadioMedix and Orano Med

Fineline Cube Sep 14, 2024

Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has entered into a significant...

Company Drug

Roche’s Tecentriq Hybreza Becomes First Subcutaneous Anti-PD-(L)1 Immunotherapy in the US

Fineline Cube Sep 14, 2024

Roche (SWX: ROG; OTCMKTS: RHHBY) , a leading Swiss pharmaceutical company, has secured US Food...

Company Drug

Lilly’s Once-Monthly Atopic Dermatitis Treatment Ebglyss Gets Green Light from FDA

Fineline Cube Sep 14, 2024

Eli Lilly & Co. (NYSE: LLY) has announced that it has received market approval from...

Company Drug

Roche’s Ocrevus Zunovo Receives FDA Nod as First Twice-Yearly MS Treatment

Fineline Cube Sep 14, 2024

Roche Group (SWX: ROG; OTCMKTS: RHHBY) , a Swiss pharmaceutical giant, has announced that the...

Company Drug

Ascentage Pharma’s Olverembatinib Shows Promise in SDH-Deficient GIST at ESMO Congress

Fineline Cube Sep 14, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced the presentation of...

Company Deals

Fosun Pharma to Acquire Full Stake in Fosun Kite Biotechnology for USD 27 Million

Fineline Cube Sep 14, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has disclosed plans to acquire...

Company Drug

Jiangsu Hengrui’s HER2-Targeted ADC SHR-A1811 Receives Priority Review from China’s NMPA

Fineline Cube Sep 14, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals Medical Device

Hangzhou-Based Ophthalmic Device Maker MDCO Secures RMB 200 Million in Series B Funding

Fineline Cube Sep 14, 2024

MDCO, an ophthalmic medical device company headquartered in Hangzhou, has reportedly secured nearly RMB 200...

Company Deals

Beijing Wantai Biological and Fujian Provincial CDC Collaborate on Vaccine Development and Public Health Initiatives

Fineline Cube Sep 14, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading biopharmaceutical company based in...

Company Deals

MGI Tech and Haihe Laboratory Deepen Collaboration with Introduction of CycloneSEQ-WT02

Fineline Cube Sep 14, 2024

MGI Tech Co., Ltd, a prominent gene sequencing company based in China, has disclosed a...

Company Deals

MGI Tech and Sequanta Technologies Launch Advanced DCS Lab to Accelerate Omics Research

Fineline Cube Sep 14, 2024

MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has entered into...

Policy / Regulatory

China Boosts Public Health Subsidies and Targets Weight Management in 2024

Fineline Cube Sep 14, 2024

The National Health Commission, Ministry of Finance, National Administration of Traditional Chinese Medicine, and National...

Policy / Regulatory

China’s NHSA and MOF Issue Notices to Enhance Cross-Regional Medical Treatment Direct Settlement

Fineline Cube Sep 14, 2024

The National Healthcare Security Administration (NHSA) and the Ministry of Finance (MOF) have issued two...

Policy / Regulatory

CDE Launches CARE Plan to Streamline Rare Disease Drug Development

Fineline Cube Sep 14, 2024

The Center for Drug Evaluation has unveiled the ‘Pilot Work Plan for Patient-Centered Action for...

Company

Moderna Inc. Announces Cost-Cutting Measures and Pipeline Realignment

Fineline Cube Sep 13, 2024

Moderna Inc. (NASDAQ: MRNA), a leading mRNA technology company based in the U.S., has announced...

Company Deals

Sino Biological and BioGeometry Broaden Partnership to Advance AI-Driven Drug Discovery

Fineline Cube Sep 13, 2024

Sino Biological (SHE: 301047), a leading biotech company in China, and BioGeometry have announced an...

Company Drug

Johnson & Johnson Submits Second NDA for Nipocalimab to Treat Generalized Myasthenia Gravis

Fineline Cube Sep 13, 2024

Johnson & Johnson (NYSE: JNJ), a leading healthcare company based in the U.S., has reported...

Company Drug

Keymed Biosciences’ IL-4Rα mAb Stapokibart Receives NMPA Approval for Atopic Dermatitis Treatment

Fineline Cube Sep 13, 2024

Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has announced that the...

Posts pagination

1 … 285 286 287 … 654

Recent updates

  • Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026
  • Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers
  • LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment
  • Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication
  • UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Company Drug

Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers

Company Drug

LEO Pharma Secures NMPA Approval for Enstilar Foam in China – First and Only Calcipotriol/Betamethasone Foam Formulation for Plaque Psoriasis Demonstrates Superior Efficacy vs. Ointment

Company Drug

Sino Biopharmaceutical’s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma – 72.4% ORR and Unreached Median PFS in Rare Cancer Indication

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.